ライフサイエンスコーパス: graft

1 recipient DCs during the life span of a skin graft.

2 oaded with peptides from leukocytes from the graft.

3 to the enhanced performance of this type of graft.

4 oplasty, while sparing a healthy endothelial graft.

5 ets and it lacks the ability to retrieve the graft.

6 sis were absent in patients with functioning graft.

7 ed interest in the use of these DIC-positive grafts.

8 uction in the biliary complications for both grafts.

9 ptum) in areas of in Eu-HP-DO3A-labeled cell grafts.

10 ti-neointimal activity of synthetic vascular grafts.

11 t significantly different from those of ABOc grafts.

12 of functional tissues and implantable tissue grafts.

13 teratomas, were observed in NT-ES-beta-cell grafts.

14 L, is needed to improve the outcomes for DCD grafts.

15 maturity were first expressed 3 months after grafting.

16 ore frequently during coronary artery bypass grafting.

17 n those who received and did not receive fat grafting.

18 er responses to these challenges than before grafting.

19 d tumor cell adhesion, migration and in vivo grafting.

20 , respectively; P < .001) and saline-labeled grafts (-0.4% +/- 6.0 vs -1.2% +/- 3.6, respectively; P

21 median CCI was significantly higher for DCD grafts (53.4 vs 47.2; P = 0.041).

22 ecipients may contribute to long-term stable graft acceptance.

23 transport can be simultaneously achieved by grafting amphiphilic diblock copolymers made of sequence

24 graft longevity and patency rates at distal graft anastomoses.

25 of portal flow and regeneration between the graft and native liver along with multiple refinements i

26 With advances in immunosuppression, graft and patient outcomes after kidney transplantation

27 t risk factors than NKAS kidneys, short-term graft and patient outcomes are acceptable.

28 ry, we examined the association between DGF, graft and patient outcomes between 1994 and 2012 using a

29 Both graft and patient survivals at most recent follow-up was

30 adults who underwent coronary artery bypass grafting and valve surgery between January 2000 and Dece

31 r-mobilized peripheral blood stem cell donor grafts and successful treatment of older recipients, chr

32 ough KFTS kidneys have less favorable donor, graft, and recipient risk factors than NKAS kidneys, sho

33 ients undergoing only coronary artery bypass grafting, and results were similar.

34 lowering their threshold for using arterial grafts, and the radial artery may be the preferred secon

35 al stem/progenitor cells for generating such grafts are easy to obtain and expand in vitro.

36 f 175 patients identified with a functioning graft at 2 years consented to enroll in an observational

37 arteriovenous fistula (AVF) or arteriovenous graft (AVG).

38 n conjunction with prevascularization of the graft bed by agarose-basic fibroblast growth factor.

39 or configuration on dimensional stability of grafted bone height after the osteotome sinus grafting p

40 Mean initial gain of sinus grafted bone height was 7.0 +/- 1.9 mm, and later it was

41 ng-term outcomes with coronary artery bypass graft (CABG) surgery compared with percutaneous coronary

42 s at 1876 hospitals), coronary artery bypass grafting (CABG) (218940 patients at 1056 hospitals), or

43 ularization by either coronary artery bypass grafting (CABG) or percutaneous coronary intervention (P

44 Grafts can be obtained from deceased or living donors, w

45 gical analysis of lymphatic vessels in donor grafts can yield information on the structure of the lym

46 r endothelial cells, as well as tumor/tissue grafts, can be encapsulated in the hydrogels during hydr

47 >300,000 tyrosine hydroxylase (TH)-positive grafted cells per side with normalized striatal TH-immun

48 th an immune response against MHC-mismatched grafted cells.

49 cularization, survival, and proliferation of grafted cells.

50 Following the procedure, the fat-grafted cohort reported similar breast satisfaction (AMD

51 sembly of nanoparticle vesicles from polymer-grafted colloids, and the closely related field of nanop

52 DG ALDLT with ABOi and ABOc graft combination seems to be a feasible option for expa

53 rchitectures thereof, e.g. block copolymers, graft copolymers or chain end functionalized assemblies.

54 for the construction of uniform hexamers and graft copolymers with precisely defined branches.

55 esistant (Namikonga) variety at 2 days after grafting (dag) (3887 DEGs) and 5 dag (4911 DEGs).

56 The grafting density (number of side chains/number of norbor

57 Grafting density and graft distribution impact the chain

58 Selective stimulation of graft-derived cells by light resulted in excitatory and

59 eakly to hundreds of MHC-bound peptides from graft-derived leukocytes.

60 Grafting density and graft distribution impact the chain dimensions and physi

61 l-2-carboxyl-propylene carbonate-graft-SMART-graft-dodecanol) (abbreviated as P-SMART), with 14.3+/-2

62 Kidney grafts donated by ODAT donors whose initial transplant o

63 adult liver transplant recipients receive a graft donation after circulatory determination of death

64 (LT), early prediction of grade 3 pulmonary graft dysfunction (PGD) remains a research gap for clini

65 In cases of irreversible intestinal graft dysfunction, isolated allograft enterectomy succes

66 Defect grafting, especially BMM+SIM, reduced inflammation and p

67 fic expression of PS-GFP in Arabidopsis, and grafting experiments, revealed that the PS mRNA moves in

68 , 95% CI: 0.98-1.04, P = .4), death-censored graft failure ( [aHR]: 1.02, 95% CI, 0.98-1.06, P = .4),

69 ficant association between CIT and all-cause graft failure (adjusted hazard ratio [aHR]: 1.01, 95% CI

70 were associated with significantly increased graft failure (P = .012).

71 nin amounts in the highest 50% had a risk of graft failure 3.59 times as high (95% confidence interva

72 ociated with a higher risk of early pancreas graft failure at 3 months.

73 Reasons for intrinsic graft failure comprised rejection, acute tubular necrosi

74 lower likelihood of retransplantation after graft failure in those aged 18 to 24 years.

75 The risk of graft failure in young kidney transplant recipients has

76 The ability to predict graft failure or primary nonfunction at liver transplant

77 females of all ages had significantly higher graft failure risks than males (adjusted hazard ratios 0

78 An index that is derived to predict graft failure using donor and recipient factors, based o

79 Acute graft failure was defined as AKI stages 1 to 3 (Acute Ki

80 The hazard of graft failure was estimated at each current age using a

81 luate management of patients with intestinal graft failure with special reference to indications and

82 ransplant factors influencing the outcome of graft failure within 30 days were selected using a machi

83 e of biliary strictures as a risk factor for graft failure, and does not validate other risk factors

84 Correlation between chimerism and rejection, graft failure, and patient survival requires further stu

85 Cumulative incidences of graft failure, cytomegalovirus, and/or adenoviral infect

86 the probability of corneal transplantation, graft failure, or both were calculated based on data fro

87 med DSA demonstrated elevated risks of early graft failure, whereas those with de novo DSA experience

88 remains the leading cause of nonimmunologic graft failure.

89 Those with impaired graft function had more graft failures; however, this result was not statistical

90 Two hundred patients were grafted from matched unrelated donor (MUD), of these, 12

91 ylamide)-co-(carboxybetaine methacrylamide)] grafted from the gold sensor surface and post modified w

92 Here, we develop skin grafts from mouse and human epidermal progenitors that w

93 Here we report an alternative grafting-from strategy for directly engineering the surf

94 Delayed graft function (DGF) is an established complication afte

95 ined the association between CIT and delayed graft function (DGF), allograft survival, and patient su

96 -reperfusion injury (IRI) leading to delayed graft function (DGF), defined by the United Network for

97 recipients, 756 of whom experienced delayed graft function (DGF).

98 rly events (acute rejection [AR] and delayed graft function [DGF] before day 90) were recorded; serum

99 nor kidney transplant [DDKT] without delayed graft function [DGF] hazard ratio: 24.634.447.9, P < 0.0

100 perfusion techniques have decreased delayed graft function and could improve graft survival.

101 ly improved graft function recovery and late graft function and reduced interstitial fibrosis after t

102 the time of implantation and achieved higher graft function at posttransplantation month 6 under simi

103 Those with impaired graft function had more graft failures; however, this re

104 before kidney removal significantly improved graft function recovery and late graft function and redu

105 Delayed graft function was also higher in uDCD than in cDCD, but

106 n independence, 6 patients (56%) had partial graft function, and 1 patient (9%) had primary graft non

107 Even in the group with stable graft function, we found a high rate of rejection (53%)

108 ere I/R injury and a predictor of poor liver graft function.

109 reperfusion are significantly correlated to graft function.

110 Relationship of AKI with delayed graft function/primary nonfunction (DGF/PNF), estimated

111 The films are formed from DNA-grafted gold nanoparticles using a layer-by-layer deposi

112 e strategies aimed at reducing injury during graft harvest and preparation represents a straightforwa

113 Fat grafting has proven to be a useful adjunct to breast rec

114 Reflecting critical trade-offs between graft health and medical comorbidities was fundamental.

115 Adults scheduled to receive bone grafting in maxillary, non-molar, single-tooth extractio

116 ts who are undergoing coronary artery bypass grafting in routine practice.

117 ipulation of the density and distribution of grafts in polymers via living ring-opening metathesis po

118 Axons emerged early from grafts in very high numbers, and half of these projectio

119 In corneal grafts, in vivo relative thickening of the En/DM is diag

120 Rodent models of graft-induced dyskinesias (GIDs) have been proposed, but

121 r early postoperative complications, such as graft infection and delayed wound healing, were seen in

122 tudy was to set up a mouse model of vascular graft infections that closely mimics the human situation

123 o evaluate the histologic characteristics of graft injury in the presence of anti-angiotensin II type

124 , consistent with the absence of progressive graft injury.

125 ft was used to supplement both SITA and BITA grafts (interaction P=0.62).

126 ioactive peptide from the annexin A1 protein grafted into a sunflower trypsin inhibitor cyclic scaffo

127 embered oxygen ring (oxetane) can be readily grafted into native peptides and proteins through site-s

128 llows them to respond directly to allogeneic grafts is a topic of much debate.

129 s and failed to reach the endocrine cells of grafted islets.

130 terial system and is believed to improve the graft longevity and patency rates at distal graft anasto

131 ications for islet survival and transplanted graft longevity.

132 ficant (HR, 1.38; 95% CI, 1.12-1.71; overall graft loss [HR, 1.08; 95% CI, 0.91-1.28]; mortality [HR,

133 We estimated the risk of death-censored graft loss and mortality after developing dementia or th

134 readmission is most strongly associated with graft loss and mortality during the readmission hospital

135 readmission is independently associated with graft loss and mortality.

136 acute rejection by 32% (OR 0.68, 0.62-0.75), graft loss by 9% (HR 0.91, 0.86-0.97), and death by 12%

137 gher incidence of overall and death-censored graft loss compared with those without DGF.

138 effective in preventing HBV reactivation and graft loss from recurrent hepatitis B after liver transp

139 d nephropathy is the second leading cause of graft loss in kidney transplant recipients.

140 s to examine the association between DGF and graft loss in pediatric and adolescent deceased donor ki

141 ctively control acute rejection and decrease graft loss in the first year after transplantation; howe

142 ose with de novo DSA experienced accelerated graft loss once DSA was detected, reaching a 28% failure

143 n fully adjusted models, only death-censored graft loss remained significant (HR, 1.38; 95% CI, 1.12-

144 After readmission, the hazard of graft loss remained, but decreased 19% per year for DDKT

145 During the readmission hospitalization, graft loss was substantially higher (deceased donor kidn

146 ated with higher risks for patient death and graft loss, although SRL + MPA was associated with a low

147 here were no associations between induction, graft loss, and incident cancer.

148 Primary endpoint was death-censored graft loss, and secondary endpoint was all-cause mortali

149 riability in modeling and reduced by 40% for graft loss.

150 se of technically successful graft survival, graft losses due to technical problems in the first 60 d

151 to improve re-endothelialization of vascular grafts, maintaining or enhancing mechanical properties w

152 alleviate this reliance on cadaveric corneal graft material.

153 The grafted MLGEPs on CNTs can obviously enhance the penetra

154 Grafting molecular precursors on partially dehydroxylate

155 Grafted monkeys were also challenged with levodopa but d

156 apply this approach to study covalently end-grafted, nanometer-thin brushes of poly(N-isopropylacryl

157 For instance, densely and sparsely grafted nanoparticles show distinct dispersion and assem

158 the density of the projections developed by grafted neurons.

159 BC fewer catecholaminergic axons entered the graft, no axons exited, and Schwann cells and astrocytes

160 aft function, and 1 patient (9%) had primary graft nonfunction.

161 Site-specific grafting of dendrons to amino acid residues on the exter

162 formation is applicable to investigating the grafting of other molecules such as self-assembled monol

163 TBSA and the need for grafting of the arm, head/neck, and trunk were significa

164 Oxetane grafting of the genetically detoxified diphtheria toxin

165 ificantly higher in C3H and C57BL/6J mice in grafts of Eu-HP-DO3A-labeled cells (40.2% +/- 5.0 vs 37.

166 average, only approximately 3.5% of proteins grafted on the SiO2-PEG8-Tf nanoparticle surface have a

167 4-carboxyphenyl layers were covalently grafted on the six electrodes by electroreduction of dia

168 ng function was significantly better in lung grafts on EVLP with a LF than in lungs on EVLP without a

169 minimal FLAG peptide (Asp-Tyr-Lys-Asp) were grafted onto a single-chain variable fragment (scFv) acc

170 dence that long CIT is a concern for reduced graft or patient survival.

171 the impact of donor HbA1c levels on pancreas graft outcomes has not been reported.

172 kidney transplants, but the impact of DGF on graft outcomes is uncertain.

173 s like the epididymal fat pad (EFP) improved graft outcomes, but only conformal coated (CC) islets ca

174 y are needed to improve long-term intestinal graft outcomes.

175 ents of EG compared to recipients of younger grafts (P < .0001).

176 Status of graft patency across time was analyzed by longitudinal n

177 eserve conduit function and possibly improve graft patency.

178 requirements and implications for long-term graft patency.

179 derstanding and predictions of these surface-grafted polymer architectures.

180 h a stiff polycyclic main chain, serves as a grafted polymer skin on the Li metal anode not only to i

181 rafted bone height after the osteotome sinus grafting procedure.

182 Liver grafts procured from heart-beating donors and preserved

183 predict and drive allograft fibrosis include graft quality, inflammation (whether "nonspecific" or re

184 pression strategies are warranted for kidney graft recipients.

185 immune cells, particularly T cells in donor grafts, recognize and eliminate leukemic cells via graft

186 he nail unit followed by full-thickness skin graft reconstruction from January 1, 2000, to August 31,

187 and increased apoptosis in vitro and in skin grafts regenerated on mice, which was correlated with re

188 ive thickening of the En/DM is diagnostic of graft rejection as measured by DMT and DRI.

189 ze allogeneic entities and that they mediate graft rejection via direct cytotoxicity and priming of a

190 in hopes of reducing relapse and decreasing graft rejection.

191 esis has been successfully used to attenuate graft rejection.

192 ADBRs included non-coronary artery bypass graft-related Thrombolysis In Myocardial Infarction majo

193 Removal of the scaffolds or kidney grafts resulted in immediate return to hyperglycemia.

194 showed enhanced systemic movement of PTGS to grafted shoots.

195 map the available epitopes on a transferrin grafted silica particle (SiO2-PEG8-Tf) as a proxy method

196 battery employing a Li metal anode with the grafted skin paired with LiNi0.5Co0.2Mn0.3O2 cathode has

197 oly (2-methyl-2-carboxyl-propylene carbonate-graft-SMART-graft-dodecanol) (abbreviated as P-SMART), w

198 jection (AMR), acute cellular rejection, and graft status.

199 pliant tissue-engineered corneal endothelial graft substitute can alleviate this reliance on cadaveri

200 ears]), the 3-year cumulative probability of graft success was 95.3% (95% CI, 93.6%-96.9%) in the 0-7

201 of 47 984 consecutive coronary artery bypass grafting surgeries performed from 1992 to 2014 among 7 m

202 syndromes or previous coronary artery bypass graft surgery in periods before (2010 through 2011) and

203 clinical outcomes in coronary artery bypass graft surgery remains unclear.

204 ary syndrome/no prior coronary artery bypass graft surgery that were rated as inappropriate decreased

205 coronary angioplasty, coronary artery bypass graft surgery, stroke).

206 previous multi-vessel coronary artery bypass graft surgery.

207 ower HA flows were associated with decreased graft survival (P = 0.013).

208 this analysis, the cumulative difference in graft survival 1 year after transplant was 115 years, an

209 Patient and graft survival after pancreas transplantation are superi

210 ith desensitization led to nearly equivalent graft survival and functional outcomes in HS pediatric p

211 chymal stromal cells can prolong solid organ graft survival and that they can induce immune tolerance

212 ant cancer had a similar overall patient and graft survival as recipients without such cancer.

213 uency of AD-MSC treatment on immunologic and graft survival as well as graft vasculopathy outcomes af

214 Pancreas graft survival at 1 year did not differ significantly be

215 Death-censored graft survival at last follow-up was 100% in the ABOi an

216 In addition, only r-ATG was associated with graft survival benefit over no-induction category (hazar

217 The preexisting DSA ABMR had superior graft survival compared with the de novo DSA ABMR (63% v

218 en and improvements in strategies to prolong graft survival could substantially reduce disparities in

219 ce the risk of DGF could potentially improve graft survival in DCD kidney transplants.

220 ns do not have a durable effect on long-term graft survival owing to a combination of drug toxicities

221 There was no difference in graft survival rate regarding the original indication of

222 kidneys, which are associated with a reduced graft survival rate, has become widely adopted in elderl

223 1-year graft survival rates are greater than 95% in many centre

224 The 5-year graft survival rates in the responding patients and the

225 Alloimmunity remains a barrier to long-term graft survival that necessitates lifelong immunosuppress

226 enting chronic allograft rejection, and that graft survival under such conditions is dependent on the

227 Ten-year posttransplant graft survival was 68.5%, 63.6%, and 65.7% for tx alone,

228 The impact of HLA mismatches on graft survival was analyzed and survival rates of transp

229 ) is to provide clinical benefit mediated by graft survival with nigrostriatal reinnervation.

230 ss ratio (ICER - cost per additional year of graft survival) within 3 years of transplantation in 19

231 ical inflammation that can negatively affect graft survival, and ignore specific risks and immune mec

232 edicare claims to estimate cumulative costs, graft survival, and incremental cost-effectiveness ratio

233 y, in-hospital mortality, metabolic outcome, graft survival, and insulin-free survival after salvage

234 n continues to provide excellent patient and graft survival, and stable renal function over 4 years.

235 In the case of technically successful graft survival, graft losses due to technical problems i

236 ll-known association of HLA antigen MMs with graft survival.

237 sed delayed graft function and could improve graft survival.

238 GCR in these lymphocyte subsets may improve graft survival.

239 ociate with a profound effect on patient and graft survival.

240 tegories, the ICER was very sensitive to the graft survival; overall both depletional antibodies were

241 mated glomerular filtration rate (eGFR), and graft-survival at 90 days and 1 year was analyzed.

242 We report a small reduction in 1-year graft-survival of kidneys from donors with AKI.

243 In grafts surviving at least 90 days, early events (acute r

244 protection devices (EPD) for saphenous vein graft (SVG) intervention; however, studies have shown co

245 oronary intervention (PCI) of saphenous vein grafts (SVGs) has historically been associated with a hi

246 he cellular composition locally in the islet graft, thereby playing a role in the autoimmune destruct

247 rejection (AMR), complement activation, and graft thrombosis.

248 ilure patients.There is a need for humanised grafts to treat patients with intestinal failure.

249 o a paper-based sensor surface via a simple "graft-to" immersion process to render the surface with b

250 ut separately for each trial (mesh trial and graft trial) some women in the standard repair arm assig

251 e parameters of 84 consecutive corneal donor grafts used for big-bubble DALK surgery between June 201

252 fungal cultures and clinical outcomes of all grafts using contaminated tissue.

253 n and transplantation significantly enhances graft vascularization, survival, and proliferation of gr

254 n and transplantation significantly enhances graft vascularization, survival, proliferation, and the

255 on immunologic and graft survival as well as graft vasculopathy outcomes after VCA.

256 t in vivo alloresponses using a severe acute graft versus host disease model.

257 Acute graft-versus-host disease (aGVHD) continues to be a freq

258 Chronic graft-versus-host disease (cGVHD) after allogeneic hemat

259 eclinical and clinical research into chronic graft-versus-host disease (cGVHD) has come to fruition i

260 ssful treatment of older recipients, chronic graft-versus-host disease (cGVHD) has emerged as the maj

261 A history of graft-versus-host disease (GVHD) ( n = 27) was associate

262 Azacitidine (AzaC) mitigates graft-versus-host disease (GvHD) in both murine preclini

263 Graft-versus-host disease (GVHD) is a complication of al

264 The risk of acute graft-versus-host disease (GVHD) is higher after allogen

265 Lower gastrointestinal (GI) tract graft-versus-host disease (GVHD) is the predominant caus

266 oth radiation exposure during transplant and graft-versus-host disease (GVHD) may increase risk of la

267 Sir) vs tacrolimus/methotrexate (Tac/Mtx) as graft-versus-host disease (GVHD) prophylaxis after match

268 les are associated with an increased risk of graft-versus-host disease (GVHD).

269 host normal tissues through the often fatal graft-versus-host disease (GVHD).

270 d HCT, myeloablative conditioning, and acute graft-versus-host disease (P values < .01).

271 clinical symptoms in animal models of acute graft-versus-host disease and multiple sclerosis.

272 ytopenias) was reported in 4 patients, acute graft-versus-host disease grade 1 in 2, grade 2 in 3, an

273 No treatment-related death or graft-versus-host disease had been reported; 15 of the 1

274 3, and grade 3-4 in 1, and moderate chronic graft-versus-host disease in 1 patient.

275 Grade II to IV acute graft-versus-host disease related to steroid treatment s

276 get tissue damage in a unique in vitro human graft-versus-host disease skin explant model.

277 Patients <50 years old and without chronic graft-versus-host disease, compared with the remaining p

278 e on Criteria for Clinical Trials in Chronic Graft-Versus-Host Disease.

279 ed immune cells can trigger life-threatening graft-versus-host disease.

280 ee-survival, nonrelapse mortality (NRM), and graft-versus-host disease.

281 t can circumvent central tolerance and limit graft-versus-host disease.

282 tively prevents GVHD while preserving strong graft-versus-leukemia (GVL) effects in allogeneic and xe

283 , recognize and eliminate leukemic cells via graft-versus-leukemia (GVL) reactivity, and transfer of

284 n clinical trials while maintaining a robust graft-versus-leukemia effect.

285 al in a mouse model of aGVHD while retaining graft-versus-leukemia effects, unveiling a novel therape

286 (MPO) in tear washes of patients with ocular graft-vs-host disease (oGVHD).

287 iciency disorders, yet complications such as graft-vs.-host disease (GvHD) limit survival.

288 sion by human Tregs in a model of xenogeneic graft-vs.-host disease induced by the transfer of human

289 ersely affect susceptibility to infection or graft-vs.-tumor immunity are hampered by the lack of a p

290 This association was present when an RA graft was used to supplement both SITA and BITA grafts (

291 BIMA grafting was associated with a reduced risk of repeat re

292 In comparison with SIMA, BIMA grafting was associated with a reduction in all-cause mo

293 Furthermore, the grafts were associated with a form of dyskinesias that r

294 Transplanted NMP grafts were matched 1:3 with transplanted SCS livers.

295 Regeneration rates of ABOi grafts were not significantly different from those of AB

296 internal mammary artery and with 1 to 4 vein grafts were recruited.

297 After EVLP, lung grafts were transplanted, and posttransplant outcomes we

298 s a promising alternative to autologous bone grafting, which is considered the current gold standard

299 Rats subcutaneously grafted with these cells were randomly assigned among th

300 , patients undergoing coronary artery bypass grafting with an internal mammary artery and with 1 to 4

301 r and inflammation after extraction and bone grafting with or without local simvastatin (SIM).